Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?
Publication date: Available online 16 October 2019Source: European Journal of RadiologyAuthor(s): Bas H.M. van der Velden, Tycho Bismeijer, Sander Canisius, Claudette E. Loo, Esther H. Lips, Jelle Wesseling, Max A. Viergever, Lodewyk F.A. Wessels, Kenneth G.A. GilhuijsAbstractPurposeTo retrospectively explore the relation between parenchymal enhancement of the healthy contralateral breast on dynamic contrast-enhanced magnetic resonance imaging (MRI) and genomic tests for estrogen receptor (ER)-pathway activity in patients with ER-positive/HER2-negative cancer.MethodsA subset of 227 consecutively included patients with unil...
Source: European Journal of Radiology - October 17, 2019 Category: Radiology Source Type: research

Single Nucleotide Polymorphisms Influence Histological Type and Grade of Canine Malignant Mammary Tumours
In this study, the relationship between the genetic profile of 87 female dogs (i.e. single nucleotide polymorphisms [SNPs] in genes known to be involved in mammary carcinogenesis) and the histological type and grade of malignant mammary tumours was assessed. The results demonstrated a significant relationship between genetic variation in genes RAD51, BRCA2, CHEK2, HER2, CDH1, COMT and PGR and these morphological features of the mammary lesions. Specifically, SNPs in RAD51 (rs23623251 and rs23642734), CHEK2 (rs397511718), HER2 (rs24537329) and PGR (rs8875007) were related to aggressive histotypes, with moderate to high hist...
Source: Journal of Comparative Pathology - October 17, 2019 Category: Pathology Source Type: research

Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer
ConclusionsAgreement between MS and surrogate classifications was generally poor. However, a post hoc analysis showed that a combination of HG and Ki67 could identify patients very likely to have Luminal A tumours according to MS. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - October 17, 2019 Category: Cancer & Oncology Source Type: research

Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
ConclusionsmTOR signaling is highly activated in TNBC tumors. As single rapalog treatment is insufficient to block mTOR signaling in rapalog-resistant TNBC cells, our results thus provide a potential multi-kinase inhibitor combinatorial strategy to overcome mTOR-targeted therapy resistance in TNBC cells. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - October 17, 2019 Category: Cancer & Oncology Source Type: research

Molecules, Vol. 24, Pages 3739: Evaluation of Cyclic Peptide Inhibitors of the Grb7 Breast Cancer Target: Small Change in Cargo Results in Large Change in Cellular Activity
field Jacqueline A. Wilce Grb7 is an adapter protein, overexpressed in HER2+ve breast and other cancers, and identified as a therapeutic target. Grb7 promotes both proliferative and migratory cellular pathways through interaction of its SH2 domain with upstream binding partners including HER2, SHC, and FAK. Here we present the evaluation of a series of monocyclic and bicyclic peptide inhibitors that have been developed to specifically and potently target the Grb7 SH2-domain. All peptides tested were found to inhibit signaling in both ERK and AKT pathways in SKBR-3 and MDA-MB-231 cell lines. Proliferation, migration, ...
Source: Molecules - October 17, 2019 Category: Chemistry Authors: Jianrong Sang Ketav Kulkarni Gabrielle M. Watson Xiuquan Ma David J. Craik S ónia T. Henriques Aaron G. Poth Aur élie H. Benfield Jacqueline A. Wilce Tags: Article Source Type: research

HER2 Positivity Predicts Unresponsiveness to EGFR‐Targeted Treatment in Metastatic Colorectal Cancer
Conclusion.Testing for HER2 should be offered to all patients with metastatic CRC because the occurrence of this biomarker is unlikely to be predicted based on main clinicopathological features. Patients with HER2‐amplified metastatic CRC are less likely to respond to anti‐EGFR therapy.Implications for Practice.Patients with HER2‐amplified/overexpressed metastatic colorectal cancer (mCRC) harbor a driver actionable molecular alteration that has been shown in preclinical models to hamper efficacy of the anti‐epidermal growth factor receptor (EGFR) targeted therapies. The present study confirmed that this molecular f...
Source: The Oncologist - October 16, 2019 Category: Cancer & Oncology Authors: Andrea Sartore-Bianchi, Alessio Amatu, Luca Porcu, Silvia Ghezzi, Sara Lonardi, Francesco Leone, Francesca Bergamo, Elisabetta Fenocchio, Erika Martinelli, Beatrice Borelli, Federica Tosi, Patrizia Racca, Emanuele Valtorta, Emanuela Bonoldi, Cosimo Martin Tags: Cancer Diagnostics and Molecular Pathology, Gastrointestinal Cancer Source Type: research

Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab
AbstractABP 980 was developed as a biosimilar to trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), that is indicated for the treatment of HER2-positive metastatic breast cancer, early breast cancer (EBC), and metastatic gastric cancer. ABP 980 is approved in the United States, European Union, and Japan for all the indications of trastuzumab, based on the totality of evidence (TOE) gathered by the systematic step-wise accumulation of comparative analytical, preclinical, and clinical (pharmacokinetics [PK], efficacy, safety and immunogenicity) data for ABP  980 and trastuzumab...
Source: Targeted Oncology - October 16, 2019 Category: Cancer & Oncology Source Type: research

Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial
ConclusionsResults from this subgroup analysis of the JACOB trial suggest similar efficacy of pertuzumab in Japanese patients and patients in the overall population, encouraging continued investigation of new agents for gastric cancer in Japanese patients. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - October 16, 2019 Category: Cancer & Oncology Source Type: research

A clinical evaluation of treatments that target cell cycle machinery in breast cancer.
Authors: Fedele P, Sanna V, Fancellu A, Cinieri S Abstract Introduction: The dysregulation of cell cycle control can lead to cancer development. In breast cancer, cyclin D, CDK 4,6 and the retinoblastoma protein play a central role in the control of cell proliferation, in crosstalk with the estrogen receptor and Her2 pathways. Although the mechanisms by which the CDK4/6 complex is involved in the control of cell growth in triple negative breast cancer (TNBC) are still unclear, some TNBCs might be sensitive to CDK4/6 inhibitors. Areas covered: The authors provide an overview of the treatments that target cell cycle ...
Source: Expert Opinion on Pharmacotherapy - October 15, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Phospholipase-C γ1 Signaling Protein Down-Regulation by Oligoclonal-VHHs based Immuno-Liposome: A Potent Metastasis Deterrent in HER2 Positive Breast Cancer Cells.
Conclusion: PLCγ1 protein levels did indeed decrease after treatment with immuno-liposome form of compounds in both two tested cell lines, verifying the inhibition ability of them. Moreover, an elevated antibody activity is associated with liposomes conjugation suggesting that immuno-liposome may be a potential target for enhancing the antibody activity. PMID: 31606964 [PubMed] (Source: Cancer Control)
Source: Cancer Control - October 15, 2019 Category: Cancer & Oncology Authors: Asadpour O, Rahbarizadeh F Tags: Cell J Source Type: research

Cancers, Vol. 11, Pages 1566: PD-1-Associated Gene Expression Signature of Neoadjuvant Trastuzumab-Treated Tumors Correlates with Patient Survival in HER2-Positive Breast Cancer
n Suwon Kim The therapeutic HER2-targeting antibody trastuzumab has been shown to elicit tumor immune response in a subset of HER2-positive (HER2+) breast cancer. We performed genomic and immunohistochemical profiling of tumors from eight patients who have completed multiple rounds of neoadjuvant trastuzumabb to identify predictive biomarkers for trastuzumab-elicited tumor immune responses. Immunohistochemistry showed that all tumors had an activated tumor immune microenvironment positive for nuclear NF-κB/p65RelA, CD4, and CD8 T cell markers, but only four out of eight tumors were positive for the PD-1...
Source: Cancers - October 15, 2019 Category: Cancer & Oncology Authors: William P. D. Hendricks Natalia Briones Rebecca F. Halperin Salvatore Facista Paul R. Heaton Daruka Mahadevan Suwon Kim Tags: Article Source Type: research

Heterogeneity and Plasticity of Human Breast Cancer Cells in Response to Molecularly-Targeted Drugs
Non-responsive subpopulation of tumor cells, and acquired resistance in initially responsive cells are major challenges for cancer therapy with molecularly-targeted drugs. While point mutations are considered the major contributing factor to acquired resistance, in this study we explored the role of heterogeneity and plasticity of selected human breast cancer cell lines (MDA-MB-231, MDA-MB-468, and AU565) in their initial and adjusted response, respectively, to ruxolitinib, everolimus, and erlotinib. After determination of lethal concentration for 50% cell death (LC50), cells were exposed to selected drugs using three diff...
Source: Frontiers in Oncology - October 15, 2019 Category: Cancer & Oncology Source Type: research

Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer
SummaryEarly stage HER2-positive cancer outcomes have been substantially improved over the last two decades, but there is still some potential for improvement. Several studies on the preoperative/postoperative treatment of HER2-positive breast cancer were presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 15, 2019 Category: Cancer & Oncology Source Type: research

Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling
Salivary duct carcinoma (SDC) is a genetically diverse malignancy associated with several potentially targetable molecular pathways that have been uncovered by comprehensive molecular profiling. Our study detected genetic aberrations in 27 of 28 cases of SDC, including targetable alterations involving PIK3CA/PTEN, BRAF, and HER2. In addition, androgen receptor splice variant AR ‐V7 was found in approximately half of cases, which has implications in resistance to anti‐androgen therapy. AbstractSalivary duct carcinoma (SDC) is a rare, aggressive salivary gland malignancy, which often presents at an advanced stage. A prop...
Source: Cancer Medicine - October 14, 2019 Category: Cancer & Oncology Authors: Stacey M. Gargano, Wijendra Senarathne, Rebecca Feldman, Elena Florento, Phillip Stafford, Jeffrey Swensen, Semir Vranic, Zoran Gatalica Tags: ORIGINAL RESEARCH Source Type: research

pH-responsive allochroic nanoparticles for the multicolor detection of breast cancer biomarkers
Publication date: Available online 11 October 2019Source: Biosensors and BioelectronicsAuthor(s): Weiqing Xu, Lei Jiao, Huarong Ye, Zhenzhong Guo, Yu Wu, Hongye Yan, Wenling Gu, Dan Du, Yuehe Lin, Chengzhou ZhuAbstractEstrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) are the three crucial biomarkers for the clinical diagnosis of breast cancer. Sensitive and precise detection of ER, PR, and HER2 is of great significance for the diagnosis of breast cancer. Herein, through a simple solvent-induced self-assembly process, the self-carried allochroic nanoparticles were prepar...
Source: Biosensors and Bioelectronics - October 13, 2019 Category: Biotechnology Source Type: research

A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer
ConclusionsTaselisib in combination with a taxane has a challenging safety profile. Despite evidence of antitumor activity, the benefit –risk profile was deemed not advantageous. Further development is not planned. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - October 12, 2019 Category: Cancer & Oncology Source Type: research

Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients
ConclusionsThe present study demonstrates that, in plasma-derived exosomes, high  baseline CDK4 mRNA levels are associated with response to palbociclib plus hormonal therapy, while the increase in TK1 and CDK9 mRNA copies/ml is associated with clinical resistance. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - October 12, 2019 Category: Cancer & Oncology Source Type: research

Transforming growth factor beta receptor II ( TGFBR2 ) promoter region polymorphism in Brazilian breast cancer patients: association with susceptibility, clinicopathological features, and interaction with TGFB1 haplotypes
ConclusionThese results indicate that G-875A is a protective factor against BC, especially from luminal-A subtype, but may promote anaplasia in established tumors, consistent with TGF β signaling roles in BC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - October 12, 2019 Category: Cancer & Oncology Source Type: research

The potential role of neutrophil trogocytosis and G-CSF in the loss of HER2 expression
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - October 12, 2019 Category: Cancer & Oncology Source Type: research

Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS
In conclusion, comparison of primary DCIS and subsequent IBC yields different results than a comparison of synchronous DCIS and IBC, in particular with regard to HER2 status. To gain more insight into the progression of DCIS to IBC, it is essential to focus on the relationship between primary DCIS and subsequent IBC, rather than comparing IBC with synchronous DCIS. (Source: The American Journal of Surgical Pathology)
Source: The American Journal of Surgical Pathology - October 12, 2019 Category: Pathology Tags: Original Articles Source Type: research

Measuring Tumor Extent Based on Subtypes Using Magnetic Resonance Imaging: Radiologic-Pathologic Discordance and High Positive Margin Rates in Breast Cancer.
Authors: Bae SJ, Ahn SG, Yoon CI, Yang BS, Lee HW, Son EJ, Jeong J Abstract Purpose: We evaluated the clinical value of breast magnetic resonance imaging (MRI) in patients who underwent breast-conserving surgery (BCS). The degree of correlation between pathology size and MRI or ultrasonography (US) size was compared based on breast cancer subtypes. In addition, we investigated the positive margin rates. Methods: Patients with invasive breast cancer who underwent preoperative breast MRI and US between 2011 and 2016 were included in the study. Lin's concordance correlation coefficient was used to measure the corr...
Source: Journal of Breast Cancer - October 12, 2019 Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research

Human Epidermal Growth Factor Receptor 2-Subtype Invasive Ductal Carcinoma Recurring as Basal-Human Epidermal Growth Factor Receptor 2-Subtype Squamous Cell Carcinoma.
We present a pathological perspective of our experience. PMID: 31598347 [PubMed] (Source: Journal of Breast Cancer)
Source: Journal of Breast Cancer - October 12, 2019 Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research

Potential Benefits of Neoadjuvant Chemotherapy in Clinically Node-Positive Luminal Subtype- Breast Cancer.
Conclusion: Despite the low pCR rate, the tumor response and BCS conversion rates after NAC of luminal HER2- breast cancer were similar to those of other subtypes. NAC has the potential benefit of reducing the size of breast cancer, thereby increasing the BCS conversion rate in luminal HER2- breast cancer. PMID: 31598341 [PubMed] (Source: Journal of Breast Cancer)
Source: Journal of Breast Cancer - October 12, 2019 Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research

Changes in Biomarker Status in Metastatic Breast Cancer and Their Prognostic Value.
Conclusion: Changes in biomarker status are not rare, and usually occur in an unfavorable direction in breast cancer metastases. Negative conversion of ER status is a predictor of poor prognosis. Thus, it is beneficial to evaluate changes in biomarker status in MBC not only for the purpose of determining treatment options but also for prognostication of patients. PMID: 31598343 [PubMed] (Source: Journal of Breast Cancer)
Source: Journal of Breast Cancer - October 12, 2019 Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research

111 In-labeled anti-cadherin17 antibody D2101 has potential as a noninvasive imaging probe for diagnosing gastric cancer and lymph-node metastasis
ConclusionOur111In-anti-CDH17 Mab D2101 depicted CDH17-positive gastric cancer xenografts in vivo and has the potential to be an imaging probe for the diagnosis of primary lesions and lymph-node metastasis in gastric cancer. (Source: Annals of Nuclear Medicine)
Source: Annals of Nuclear Medicine - October 12, 2019 Category: Nuclear Medicine Source Type: research

Neurotensin receptors regulate transactivation of the EGFR and HER2 in a reactive oxygen species-dependent manner.
Abstract Neurotensin is a 13 amino acid peptide which is present in many lung cancer cell lines. Neurotensin binds with high affinity to the neurotensin receptor 1, and functions as an autocrine growth factor in lung cancer cells. Neurotensin increases tyrosine phosphorylation of the epidermal growth factor receptor (EGFR) and the neurotensin receptor 1 antagonist SR48692 blocks the transactivation of the EGFR. Here the effects of reactive oxygen species on the transactivation of the EGFR and HER2 were investigated. Using non-small cell lung cancer (NSCLC) cell lines, neurotensin receptor 1 mRNA and protein were p...
Source: European Journal of Pharmacology - October 12, 2019 Category: Drugs & Pharmacology Authors: Moody TW, Lee L, Ramos-Alvarez I, Jensen RT Tags: Eur J Pharmacol Source Type: research

An aptamer-based colorimetric lateral flow assay for the detection of human epidermal growth factor receptor 2 (HER2).
In this study, two approaches were examined using HER2 binding aptamers and gold nanoparticles. The first method used was a solution-based adsorption-desorption colorimetric approach wherein aptamers were adsorbed onto the gold nanoparticle surface. Upon the addition of HER2, HER2 binds specifically with its aptamer, releasing the gold nanoparticles. Addition of NaCl then induces the formation of gold nanoparticle aggregates. This leads to a color change from red to blue and a detection limit of 10 nM was achieved. The second method used an adsorption-desorption colorimetric lateral flow assay approach wherein biotin-mod...
Source: Analytical Biochemistry - October 12, 2019 Category: Biochemistry Authors: Ranganathan V, Srinivasan S, Singh A, DeRosa MC Tags: Anal Biochem Source Type: research

Droplet microfluidic platform for fast and continuous-flow RT-qPCR analysis devoted to cancer diagnosis application
Publication date: Available online 5 October 2019Source: Sensors and Actuators B: ChemicalAuthor(s): I. Hajji, M. Serra, L. Geremie, I. Ferrante, R. Renault, J.-L. Viovy, S. Descroix, D. FerraroAbstractRT-qPCR represents a key method in cancer diagnostic, however the constant increase in patients and cancer biomarker panels to screen requires the implementation of faster approaches allowing smaller reagents and samples volumes consumption. To fulfil these needs, we present here a fully automated droplet microfluidics platform that couples a specifically designed thermal system with a fluorescent excitation/detection module...
Source: Sensors and Actuators B: Chemical - October 11, 2019 Category: Chemistry Source Type: research

Preparation of Diphtheria and Pseudomonas Exotoxin A Immunotoxins and Evaluation of Their Cytotoxicity Effect on SK-BR-3, BT-474, and MDA-MB-231 Breast Cancer Cell Lines.
In this study, we introduce immunotoxins comprising of truncated pseudomonas exotoxin A (PEA) and diphtheria toxin (DT) conjugated to trastuzumab. The effectiveness of 20 and 30 μg/ml immunotoxins and trastuzumab were studied on SK-BR-3 and BT-474 HER2/neu positive breast cancer cell lines by a cell death assay test. The produced immunotoxins have the potential to reduce the therapeutic dose of the trastuzumab and in the same time achieve higher efficiency. PMID: 31597492 [PubMed - as supplied by publisher] (Source: Cancer Investigation)
Source: Cancer Investigation - October 11, 2019 Category: Cancer & Oncology Tags: Cancer Invest Source Type: research

Suboptimal concordance in testing and retesting results of triple-negative breast carcinoma cases among laboratories: one institution experience
Triple-negative breast carcinoma (TNBC) patients do not benefit from hormone- or human epidermal growth factor receptor 2- (HER2-) targeted therapies. Accurate testing is pivotal for these patients. (Source: Cancer Cell International)
Source: Cancer Cell International - October 11, 2019 Category: Cancer & Oncology Authors: Jose De Jesus and Marilin Rosa Tags: Primary research Source Type: research

A pooled analysis of the cardiac events in the trastuzumab adjuvant trials
ConclusionOne year of trastuzumab increases the risk of cardiac events, though most consist of asymptomatic or mildly symptomatic LVEF drops. Adjuvant trastuzumab should be considered a safe treatment from a cardiac standpoint for most patients. Trastuzumab-associated cardiotoxicity is the main cause of discontinuation and further research is needed to individualize prevention and management. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - October 11, 2019 Category: Cancer & Oncology Source Type: research

Targeted and novel therapy in advanced gastric cancer
AbstractThe systemic treatment options for advanced gastric cancer (GC) have evolved rapidly in recent years. We have reviewed the recent data of clinical trial incorporating targeted agents, including inhibitors of angiogenesis, human epidermal growth factor receptor 2 (HER2), mesenchymal –epithelial transition, epidermal growth factor receptor, mammalian target of rapamycin, claudin-18.2, programmed death-1 and DNA. Addition of trastuzumab to platinum-based chemotherapy has become standard of care as front-line therapy in advanced GC overexpressing HER2. In the second-line setting , ramucirumab with paclitaxel sign...
Source: Experimental Hematology and Oncology - October 11, 2019 Category: Cancer & Oncology Source Type: research

The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.
Stephens PJ, Zhu VW, Ou SI, Lovly CM, Gounder M, Schrock AB, Ross JS, Miller VA, Klempner SJ, Ali SM Abstract PURPOSE: Amplifications of receptor tyrosine kinases (RTKS) are therapeutic targets in multiple tumor types (e.g. HER2 in breast cancer), and amplification of the chromosome 4 segment harboring the three RTKs KIT, PDGFRA, and KDR (4q12amp) may be similarly targetable. The presence of 4q12amp has been sporadically reported in small tumor specific series but a large-scale analysis is lacking. We assess the pan-cancer landscape of 4q12amp and provide early clinical support for the feasibility of targeting th...
Source: The Oncologist - October 11, 2019 Category: Cancer & Oncology Authors: Disel U, Madison R, Abhishek K, Chung JH, Trabucco SE, Matos AO, Frampton GM, Albacker LA, Reddy V, Karadurmus N, Benson A, Webster J, Paydas S, Cabanillas R, Nangia C, Ozturk MA, Millis SZ, Pal SK, Wilky B, Sokol ES, Gay LM, Soman S, Ganesan S, Janeway K Tags: Oncologist Source Type: research

Role of dose-dense chemotherapy in high-risk early breast cancer
In conclusion, high-risk early stage breast cancer patients should be treated with (neo)adjuvant dose-dense anthracycline-based chemotherapy followed by paclitaxel. In the era of trastuzumab, the benefit of dose-dense chemotherapy is still unclear for patients with HER2-positive breast cancer. (Source: Current Opinion in Oncology)
Source: Current Opinion in Oncology - October 10, 2019 Category: Cancer & Oncology Tags: BREAST CANCER: Edited by Giuseppe Curigliano Source Type: research

Prognostic factors associated with survival in a large cohort of gastric cancer patients resected over a decade at a single Italian center: the Cremona experience
AbstractBackgroundIncidence of gastric cancer (GC) shows different distribution in Italy, with higher incidence in the north and center. We retrospectively analyzed the clinical data of patients resected at the Hospital of Cremona between January 2007 and December 2016. Available clinical variables were linked with survival to identify possible prognostic factors.Materials and methodsVariables analyzed were age, sex, type of surgery, site, histology, invasion, nodal status, resection margins, grade, HER2 status,Helicobacter pylori infection (neo)adjuvant chemotherapy, adjuvant chemoradiotherapy, neutrophil-to-lymphocyte ra...
Source: Clinical and Translational Oncology - October 10, 2019 Category: Cancer & Oncology Source Type: research

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer
ConclusionFurther functional studies to decipher the role of IDH2 and its mechanism of action as a driver of BC progression and LVI are warranted. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - October 10, 2019 Category: Cancer & Oncology Source Type: research

miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer.
In this study, we used HER2-positive SKBR3, HER2-negative MCF-7, and their CD44+ CD24- phenotype mammospheres SKBR3-S and MCF-7-S to verify. Our results demonstrated that miR-200c was weakly expressed in breast cancer cell lines and cell line stem cells. Overexpression of miR-200c resulted in a significant reduction in the number of tumour spheres formed and the population of CD44+ CD24- phenotype mammospheres in SKBR3-S. Combining miR-200c with trastuzumab can significantly reduce proliferation and increase apoptosis of SKBR3 and SKBR3-S. Overexpression of miR-200c also eliminated its downstream target genes. These genes ...
Source: J Cell Mol Med - October 10, 2019 Category: Molecular Biology Authors: Tang H, Song C, Ye F, Gao G, Ou X, Zhang L, Xie X, Xie X Tags: J Cell Mol Med Source Type: research

Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy
Publication date: 8 October 2019Source: Cell Reports, Volume 29, Issue 2Author(s): Alison Hirukawa, Salendra Singh, Jarey Wang, Jonathan P. Rennhack, Matthew Swiatnicki, Virginie Sanguin-Gendreau, Dongmei Zuo, Kamilia Daldoul, Cynthia Lavoie, Morag Park, Eran R. Andrechek, Thomas F. Westbrook, Lyndsay N. Harris, Vinay Varadan, Harvey W. Smith, William J. MullerSummaryMonoclonal antibodies (mAbs) targeting the oncogenic receptor tyrosine kinase ERBB2/HER2, such as Trastuzumab, are the standard of care therapy for breast cancers driven by ERBB2 overexpression and activation. However, a substantial proportion of patients exhi...
Source: Cell Reports - October 9, 2019 Category: Cytology Source Type: research

Anti-CV2 Autoimmune Encephalitis With Parkinson-Like Symptoms and Bilateral Leukoencephalopathy —A Case Report
Conclusion: Anti-CV2 autoimmune encephalitis can present as Parkinsonism with bilateral leukoencephalopathy on MRI. PET scanning can be useful to reveal an occult cancer. Treatment of the cancer may improve the paraneoplastic neurological syndrome without the need of immunosuppressive therapy. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - October 9, 2019 Category: Neurology Source Type: research

Trastuzumab/Hyaluronidase-oysk: A New Option for Patients With HER2-Positive Breast Cancer.
CONCLUSIONS: SQ trastuzumab has a similar safety profile to IV trastuzumab. Although it may be slightly more cost-effective, its role in the treatment of HER2-overexpressing tumors requires further study in those at the extremes of body weight due to differences in drug exposure compared to IV trastuzumab. PMID: 31595774 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 9, 2019 Category: Drugs & Pharmacology Authors: Duco MR, Murdock JL, Reeves DJ Tags: Ann Pharmacother Source Type: research

Randomized phase 0/I trial of the mitochondrial inhibitor ME-344 or placebo added to bevacizumab in early HER2-negative breast cancer.
E, Mulero F, Mourón S Abstract BACKGROUND: We previously demonstrated that mitochondrial inhibitors efficacy was restricted to a metabolic context in which mitochondrial respiration was the predominant energy source, a situation achievable by inducing vascular normalization/hypoxia correction with antiangiogenics. Vascular normalization can be tracked with FDG-PET. We tested the efficacy of the mitochondrial inhibitor ME-344 or placebo added to bevacizumab in early breast cancer. METHODS: Treatment-naïve HER2-negative patients with T>1cm (any N) underwent a breast-centered FDG-PET (day 1) and ...
Source: Clinical Cancer Research - October 9, 2019 Category: Cancer & Oncology Authors: Quintela-Fandino M, Morales S, Cortés-Salgado A, Manso L, Apala JV, Muñoz M, Gasol Cudos A, Salla Fortuny J, Gion M, Lopez-Alonso A, Cortés J, Guerra J, Malón D, Caleiras E, Mulero F, Mourón S Tags: Clin Cancer Res Source Type: research

A Genome-Wide Association Study Identifies Five Novel Genetic Markers for Trastuzumab-Induced Cardiotoxicity in Japanese Population.
Abstract Trastuzumab has been administered to patients with HER2-positive cancer, however, the cardiotoxicity is identified as one of the life-threatening toxicities. Clinically useful biomarker for trastuzumab-induced cardiotoxicity has been expected to be developed. To identify a novel genetic marker(s) determining the risk of trastuzumab-induced cardiotoxicity, we performed a first genome-wide association study (GWAS) in Japanese population. We enrolled 481 patients who had been treated with trastuzumab and carried out a GWAS using 11 cases (with cardiotoxicity) and 257 controls (without cardiotoxicity). Top 10...
Source: Biological and Pharmaceutical Bulletin - October 9, 2019 Category: Drugs & Pharmacology Authors: Nakano MH, Udagawa C, Shimo A, Kojima Y, Yoshie R, Zaha H, Abe N, Motonari T, Unesoko M, Tamura K, Shimoi T, Yoshida M, Yoshida T, Sakamoto H, Kato K, Mushiroda T, Tsugawa K, Zembutsu H Tags: Biol Pharm Bull Source Type: research

Chromosome 17 centromere amplification and chromosomal instability (CIN) in breast cancer: Pathogenic and therapeutic implications.
Abstract Chromosomal instability (CIN) is present in variable degrees in a significant percentage (up to 90%) of cancers and often portends adverse outcomes. However, it has not been incorporated in clinical practice as a prognostic marker due to lack of standardization and proof of clinical utility of assays to measure it, as well as uncertainties regarding optimal cut-offs. Amplification of the centromeric region of chromosome 17 as measured by In Situ Hybridization (ISH) of the CEP17 probe is used clinically as part of the ISH assay for HER2 status determination in breast cancer in cases with intermediate (2+) ...
Source: Neoplasma - October 9, 2019 Category: Cancer & Oncology Authors: Voutsadakis IA Tags: Neoplasma Source Type: research

Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1
ConclusionsGC patients who exhibited markers that can serve as an indication for known targeted therapy represent 40.4% of cases. The IT group was associated with a better prognosis. No benefit with standard adjuvant treatment appears to be achieved in MSI/PD-L1+ GCs. (Source: Molecular Diagnosis and Therapy)
Source: Molecular Diagnosis and Therapy - October 8, 2019 Category: Molecular Biology Source Type: research

Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial.
CONCLUSION: POC reduced the incidence and severity of oral mucositis in patients receiving everolimus and exemestane. This might be considered as a treatment option of oral care for patients undergoing this treatment. Clinical trial identification number: NCT02069093. IMPLICATIONS FOR PRACTICE: The Oral Care-BC trial that prophylactically used professional oral care (POC), available worldwide, did not show a greater than 25% difference in mucositis. The 12% difference in grade 1 or higher mucositis and especially the ∼20% difference in grade 2 mucositis are likely clinically meaningful to patients. POC before trea...
Source: The Oncologist - October 8, 2019 Category: Cancer & Oncology Authors: Niikura N, Nakatukasa K, Amemiya T, Watanabe KI, Hata H, Kikawa Y, Taniike N, Yamanaka T, Mitsunaga S, Nakagami K, Adachi M, Kondo N, Shibuya Y, Hayashi N, Naito M, Kashiwabara K, Yamashita T, Umeda M, Mukai H, Ota Y Tags: Oncologist Source Type: research

PET imaging of a 68Ga labeled modified HER2 affibody in breast cancers: from xenografts to patients.
CONCLUSION: In summary, this study indicates the significant efficiency of the 68Ga labeled HER2 affibody. Preclinical and clinical studies support the possibility of monitoring HER2 levels in breast cancers using 68Ga-NOTA-MAL-Cys-MZHER2:342. ADVANCES IN KNOWLEDGE: The research investigated the feasibility of a 68Ga labeled HER2 affibody modified with a hydrophilic linker for breast cancer PET imaging. Favorable outcomes showed that the probe might be valuable for determining HER2 status of the disease. PMID: 31593482 [PubMed - as supplied by publisher] (Source: The British Journal of Radiology)
Source: The British Journal of Radiology - October 8, 2019 Category: Radiology Authors: Xu Y, Wang L, Pan D, Yu C, Mi B, Huang Q, Sheng J, Yan J, Wang X, Yang R, Yang M Tags: Br J Radiol Source Type: research

Syntheses and functional studies of self-adjuvanting anti-HER2 cancer vaccines.
Abstract A 9-mer peptide MFCH401 (N: 165-173: DTILWKDIF), which is located in the extracellular domain of HER2, has been predicted to be a novel epitope. Self-adjuvanting anti-HER2 vaccine constructs were designed and synthesized via covalently attached MFCH401 or its linear tandem repeats (2×MFCH401, 3×MFCH401) to a lipopeptide Pam3CSK4 via iterative condensation reaction. The in vivo results showed the Pam3CSK4-MFCH401 vaccine construct can induce higher antibody titers of IgG and IgM than that of other conjugates, and the analysis of changes in plasma cytokines level indicating the activation of Th1...
Source: Chemistry, an Asian Journal - October 7, 2019 Category: Chemistry Authors: Feng Q, Manabe Y, Kabayama K, Aiga T, Miyamoto A, Ohshima S, Kametani Y, Fukase K Tags: Chem Asian J Source Type: research

Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine therapy resistance.
CONCLUSIONS: Our research identifies multiple therapeutic opportunities for advanced breast cancer and identifies the previously underappreciated acquisition of NF1 mutations. PMID: 31591187 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 7, 2019 Category: Cancer & Oncology Authors: Pearson A, Proszek PZ, Pascual J, Fribbens C, Shamsher MK, Kingston B, O'Leary B, Herrera-Abreu MT, Cutts RJ, Garcia-Murillas I, Bye H, Walker BA, Gonzalez De Castro D, Yuan L, Jamal S, Hubank M, López-Knowles E, Schuster EF, Dowsett M, Osin P, Nerurkar Tags: Clin Cancer Res Source Type: research

Evaluations of Biomarker Status Changes between Primary and Recurrent Tumor Tissue Samples in Breast Cancer Patients.
Conclusion: A substantial discordance in ER, PR, and HER2 status were observed between primary breast cancer tissues and recurrent lesions. Rebiopsy could bring new therapeutic opportunities in the management of patients with recurrent breast cancer. PMID: 31583246 [PubMed - in process] (Source: Biomed Res)
Source: Biomed Res - October 6, 2019 Category: Research Authors: Nguyen TH, Nguyen VH, Nguyen TL, Qiuyin C, Phung TH Tags: Biomed Res Int Source Type: research

21-Gene recurrence score influences the chemotherapy decision for patients with breast cancer of different luminal subtypes.
In conclusion, luminal subtypes and the 21-gene RS were found to be associated with chemotherapy recommendation for HR+/HER2- patients. For patients with a discordant luminal subtype and 21-gene RS risk, the 21-gene RS score was found to be the most important factor that influences chemotherapy decision, which warrants further clinical evaluation. PMID: 31579428 [PubMed] (Source: Oncology Letters)
Source: Oncology Letters - October 5, 2019 Category: Cancer & Oncology Tags: Oncol Lett Source Type: research